These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 12854232)

  • 21. Effectiveness of risedronate in osteoporotic postmenopausal women with inflammatory bowel disease: a prospective, parallel, open-label, two-year extension study.
    Palomba S; Manguso F; Orio F; Russo T; Oppedisano R; Sacchinelli A; Falbo A; Tolino A; Zullo F; Mastrantonio P
    Menopause; 2008; 15(4 Pt 1):730-6. PubMed ID: 18698280
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Value of fluoride therapy in osteoporosis].
    Ringe JD
    Fortschr Med; 1997 Oct; 115(29):30-2, 34, 36. PubMed ID: 9445832
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Your patients face the treatment of osteoporosis: How to improve the efficacy of management in clinical practice?].
    Thomas T; Reach G; Lespessailles E
    Rev Prat; 2006 Jan; Spec No():3-11. PubMed ID: 16502833
    [No Abstract]   [Full Text] [Related]  

  • 24. Potential impact of osteoporosis treatment on hip fracture trends.
    Melton LJ; Kanis JA; Johnell O
    J Bone Miner Res; 2005 Jun; 20(6):895-7. PubMed ID: 15883627
    [No Abstract]   [Full Text] [Related]  

  • 25. [FACT study: benefits of alendronate].
    MMW Fortschr Med; 2005 Jan; 147(1-2):52-3. PubMed ID: 15704574
    [No Abstract]   [Full Text] [Related]  

  • 26. [Treating with what? Therapy for how long?].
    MMW Fortschr Med; 2005 Dec; 147(51-52):62-3. PubMed ID: 16402713
    [No Abstract]   [Full Text] [Related]  

  • 27. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
    Iwamoto J; Takeda T; Sato Y
    Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost effectiveness and cost utility of risedronate for osteoporosis treatment and fracture prevention in women: a Swiss perspective.
    Wasserfallen JB; Krieg MA; Greiner RA; Lamy O
    J Med Econ; 2008; 11(3):499-523. PubMed ID: 19450101
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Delaying degeneration or promoting regeneration. 2 successful strategies in osteoporosis].
    MMW Fortschr Med; 2004 Mar; 146(10):46. PubMed ID: 15347088
    [No Abstract]   [Full Text] [Related]  

  • 30. Pharmacologic prevention of osteoporotic fractures.
    Zizic TM
    Am Fam Physician; 2004 Oct; 70(7):1293-300. PubMed ID: 15508540
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Optimizing treatment of osteoporosis. Rapidly effective therapy lowers fracture risk in 1 year up to 70%].
    MMW Fortschr Med; 2001 Sep; 143(35-36):50. PubMed ID: 11584531
    [No Abstract]   [Full Text] [Related]  

  • 32. Do not use bisphosphonate therapy indefinitely for fracture prevention.
    Prescrire Int; 2008 Oct; 17(97):214. PubMed ID: 19536944
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Consistent therapeutic success in osteoporosis].
    Krankenpfl J; 2004; 42(3-4):100-1. PubMed ID: 15311900
    [No Abstract]   [Full Text] [Related]  

  • 34. Parathyroid hormone.
    Madore GR; Sherman PJ; Lane JM
    J Am Acad Orthop Surg; 2004; 12(2):67-71. PubMed ID: 15089079
    [No Abstract]   [Full Text] [Related]  

  • 35. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
    Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
    Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of postmenopausal osteoporosis with etidronate.
    Heyneman CA
    Ann Pharmacother; 1993 Oct; 27(10):1200-1. PubMed ID: 8251688
    [No Abstract]   [Full Text] [Related]  

  • 37. Five years of treatment with risedronate and its effects on bone safety in women with postmenopausal osteoporosis.
    Ste-Marie LG; Sod E; Johnson T; Chines A
    Calcif Tissue Int; 2004 Dec; 75(6):469-76. PubMed ID: 15478000
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Osteoporosis treatment: the point of view of the gynecologist].
    Lopes P
    Contracept Fertil Sex; 1998 Jun; 26(6):408-11. PubMed ID: 9691516
    [No Abstract]   [Full Text] [Related]  

  • 39. [Risedronate (Actonel)--from randomized clinical trials to real life].
    Anić B
    Reumatizam; 2007; 54(2):85-6. PubMed ID: 18351152
    [No Abstract]   [Full Text] [Related]  

  • 40. Pharmacoeconomic analysis of osteoporosis treatment with risedronate.
    Brecht JG; Kruse HP; Felsenberg D; Möhrke W; Oestreich A; Huppertz E
    Int J Clin Pharmacol Res; 2003; 23(4):93-105. PubMed ID: 15224498
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.